Alopecia Treatment Market to Propel as Researchers Present Treatment to Regrow Hair
Posted On July 22, 2022
An autoimmune condition called alopecia areata causes the body's immune system to assault hair follicles. In the United States, more than 200,000 new cases are reported yearly. Although individuals of any age can acquire alopecia areata, it mainly affects persons under the age of 40. The disease currently has no FDA-approved treatments.
A new study brought forth is based on Phase 3 clinical trials wherein the researchers used the Janus kinase (JAK) inhibitor baricitinib. They successfully treated alopecia areata, a frequently disfiguring skin condition marked by rapid loss of scalp hair and occasionally eyebrows and eyelashes. The achievement is highly relevant for the Alopecia Treatment Market as a common arthritis medication may help one out of every three patients with a severe skin disease regrow hair.
Phase 3 clinical studies are a must before a new medicine may be considered for U.S. Food and Drug Administration (FDA) clearance.
The research data unambiguously demonstrates baricitinib's effectiveness, which is why this is so intriguing. These extensive, well-controlled studies show that one can lessen some of the pain caused by this terrible illness.
The team used a total of 1,200 participants in two significant randomized trials for the new investigation. Participants received either 4 milligrammes of baricitinib, 2 milligrammes of baricitinib, or a placebo every day for 36 weeks. 33.33% of the patients who received the larger dose grew their hair back. Adults with severe alopecia areata who had lost at least 50% of their scalp hair and all of it made up the participants.
According to the researchers, baricitinib prevents the condition by obstructing the immune cells' communication ability, which harms hair follicles. Joint diseases with autoimmune causes are frequently treated with baricitinib and other JAK inhibitors.
The study's findings were made public during the American Academy of Dermatology's annual meeting. The group has created strategies for using JAK inhibitors to treat a range of skin conditions, such as sarcoidosis , vitiligo, granuloma annulare, eczema, and erosive lichen planus, over the past ten years.
At last, researchers mentioned that baricitinib clinical trials are still ongoing, allowing experts to evaluate the medication's long-term efficacy and safety.